Oh yeah! These guys are undoubtedly some of the most supportive directors in the listed Med Tech sector. They have poured good money after bad into CDX.
'"badly managed till now" is all well and good. Problem is, both Cooper/Cairns have been architects of their own misfortune.
Either.... they have a great strategy, are executive effectively and all is well, they just need a bit more time and a few more $ to get CDX to the point where they start kicking commercial goals, investor sentiment/ASX/NASDAQ is against them and the US IPO was bad luck/timing... OR ....
...they are out of their depth hands-on running a digital/medTech and are learning on the hoof, have mistakenly pursued market applications for their tech that are either not living up to their expectations or their market analysis/expectations were poorly conceived, can't shift product because their IP/tech/USP isn't compelling enough to change existing habits and maybe 'customers' aren't excited at the offerings and were deluded to think US investors were naiively advised.
Or something
Add to My Watchlist
What is My Watchlist?
